| Abstract/Notes |
Abstract: Fibromyalgia is a neurosensory disorder characterized by chronic musculocutaneous pain. The initial approach in terms of pharmaceutical agents includes selective serotonin-norepinephrine reuptake inhibitors like duloxetine and milnacipran which has conflicting evidence on its efficacy. In 2012, Hauser, et al, carried out a literature review of 10 studies involving over 6000 patients. This study found that duloxetine and milnacipran were not superior to placebo in reducing sleep problems. Also, in 2012, Arnold, et al, designed a double-blind, placebo-controlled, randomized controlled trial of several countries involving over 300 patients. In this study, duloxetine did not significantly reduce pain severity in patients with fibromyalgia. Finally, in 2019, Himanshu, et al, conducted a double-blind, placebo-controlled, randomized controlled trial of 149 patients with juvenile fibromyalgia. In this study, mean change in 24-hour brief pain inventory average severity rating from baseline to Week 13 did not significantly improve with duloxetine compared to placebo in patients with juvenile fibromyalgia.
This abstract is reproduced with the permission of the publisher.
|
